Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Lung Cancer | Research article

Artificial intelligence-supported lung cancer detection by multi-institutional readers with multi-vendor chest radiographs: a retrospective clinical validation study

Authors: Daiju Ueda, Akira Yamamoto, Akitoshi Shimazaki, Shannon Leigh Walston, Toshimasa Matsumoto, Nobuhiro Izumi, Takuma Tsukioka, Hiroaki Komatsu, Hidetoshi Inoue, Daijiro Kabata, Noritoshi Nishiyama, Yukio Miki

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

We investigated the performance improvement of physicians with varying levels of chest radiology experience when using a commercially available artificial intelligence (AI)-based computer-assisted detection (CAD) software to detect lung cancer nodules on chest radiographs from multiple vendors.

Methods

Chest radiographs and their corresponding chest CT were retrospectively collected from one institution between July 2017 and June 2018. Two author radiologists annotated pathologically proven lung cancer nodules on the chest radiographs while referencing CT. Eighteen readers (nine general physicians and nine radiologists) from nine institutions interpreted the chest radiographs. The readers interpreted the radiographs alone and then reinterpreted them referencing the CAD output. Suspected nodules were enclosed with a bounding box. These bounding boxes were judged correct if there was significant overlap with the ground truth, specifically, if the intersection over union was 0.3 or higher. The sensitivity, specificity, accuracy, PPV, and NPV of the readers’ assessments were calculated.

Results

In total, 312 chest radiographs were collected as a test dataset, including 59 malignant images (59 nodules of lung cancer) and 253 normal images. The model provided a modest boost to the reader’s sensitivity, particularly helping general physicians. The performance of general physicians was improved from 0.47 to 0.60 for sensitivity, from 0.96 to 0.97 for specificity, from 0.87 to 0.90 for accuracy, from 0.75 to 0.82 for PPV, and from 0.89 to 0.91 for NPV while the performance of radiologists was improved from 0.51 to 0.60 for sensitivity, from 0.96 to 0.96 for specificity, from 0.87 to 0.90 for accuracy, from 0.76 to 0.80 for PPV, and from 0.89 to 0.91 for NPV. The overall increase in the ratios of sensitivity, specificity, accuracy, PPV, and NPV were 1.22 (1.14–1.30), 1.00 (1.00–1.01), 1.03 (1.02–1.04), 1.07 (1.03–1.11), and 1.02 (1.01–1.03) by using the CAD, respectively.

Conclusion

The AI-based CAD was able to improve the ability of physicians to detect nodules of lung cancer in chest radiographs. The use of a CAD model can indicate regions physicians may have overlooked during their initial assessment.
Appendix
Available only for authorised users
Literature
2.
go back to reference Manser R, Lethaby A, Irving LB, Stone C, Byrnes G, Abramson MJ, et al. Screening for lung cancer. Cochrane Database of Systematic Reviews. 2013;2013:Cd001991. Manser R, Lethaby A, Irving LB, Stone C, Byrnes G, Abramson MJ, et al. Screening for lung cancer. Cochrane Database of Systematic Reviews. 2013;2013:Cd001991.
23.
go back to reference Kripalani S, Williams MV, Rask K. Reducing errors in the interpretation of plain radiographs and computed tomography scans. In. 2001;2001. Kripalani S, Williams MV, Rask K. Reducing errors in the interpretation of plain radiographs and computed tomography scans. In. 2001;2001.
Metadata
Title
Artificial intelligence-supported lung cancer detection by multi-institutional readers with multi-vendor chest radiographs: a retrospective clinical validation study
Authors
Daiju Ueda
Akira Yamamoto
Akitoshi Shimazaki
Shannon Leigh Walston
Toshimasa Matsumoto
Nobuhiro Izumi
Takuma Tsukioka
Hiroaki Komatsu
Hidetoshi Inoue
Daijiro Kabata
Noritoshi Nishiyama
Yukio Miki
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08847-9

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine